Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Kailera Therapeutics, Inc. (KLRA) AI Stock Analysis

61 Followers
KLRA

Kailera Therapeutics, Inc.

(NASDAQ:KLRA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Kailera Therapeutics, Inc. (KLRA) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%KLRA-44.69%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.87B
Dividend Yield
―
Average Volume (3M)
1.11M
Price to Earnings (P/E)
-5.8
Beta (1Y)
1.48
Revenue Growth
―
EPS Growth
―
Country
US
Employees
145
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Kailera Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectabl...

Kailera Therapeutics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

KLRA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TARSTARS67Neutral$3.64B-5.05-245.72%―86.34%-654.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TRVITRVI48Neutral$2.13B-38.20-24.81%――-6.57%
ACRSACRS47Neutral$658.24M-7.48-59.20%―-59.34%57.30%
BEAMBEAM46Neutral$2.60B-25.81-9.69%―163.27%77.49%
OCULOCUL45Neutral$1.45B-4.56-59.50%―-9.68%-1.35%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%KLRAOCULACRSTRVIBEAMTARSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KLRA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KLRAKailera Therapeutics, Inc.14.38-11.62-44.69%
OCULOcular Therapeutix Inc6.66-4.53-40.48%
ACRSAclaris Therapeutics Inc.4.342.0287.07%
TRVITrevi Therapeutics14.813.3529.28%
BEAMBeam Therapeutics, Inc.25.814.1519.16%
TARSTarsus Pharmaceuticals, Inc.76.764.235.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.